EP1432817A4 - Methods and arrays for detecting biological molecules - Google Patents
Methods and arrays for detecting biological moleculesInfo
- Publication number
- EP1432817A4 EP1432817A4 EP02742197A EP02742197A EP1432817A4 EP 1432817 A4 EP1432817 A4 EP 1432817A4 EP 02742197 A EP02742197 A EP 02742197A EP 02742197 A EP02742197 A EP 02742197A EP 1432817 A4 EP1432817 A4 EP 1432817A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- support
- reagents
- antibodies
- immobilized
- ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00387—Applications using probes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00513—Essentially linear supports
- B01J2219/0052—Essentially linear supports in the shape of elongated tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00572—Chemical means
- B01J2219/00576—Chemical means fluorophore
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00673—Slice arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00675—In-situ synthesis on the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00677—Ex-situ synthesis followed by deposition on the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
- B01J2219/00743—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention generally relates to novel methods and arrays for detecting a plurality of proteins and more particularly to methods and arrays for detecting the expressions, activities and functions of multiple proteins.
- DNA arrays are used in large-scale hybridization assays for applications such as monitoring gene expressions (Schena et al., 1995, Science 270:467-470; DeRisi et al., 1996, Nature Genetics 14:457-460).
- Arrays of DNA clones in expression vectors are also used to express their encoded proteins in mammalian cells (Ziauddin and Sabatini, 2001, Nature 411, 107-110). h a protein array, many proteins are immobilized on a support, each at a predetermined position so that it can be identified subsequently by this unique position.
- antibody arrays Two types of protein arrays are particularly useful: antibody arrays and recombinant protein arrays, which contain a plurality of antibodies and a plurality of recombinant proteins, respectively. Because antibody arrays are capable of binding cellular proteins, they are particularly useful in revealing protein in vivo activities. Therefore, the technology makes it possible to study the properties of a large number of cellular proteins in a single assay. Specifically, antibody arrays have been applied in studying in vivo protein-protein interactions, protein posttranslational modifications and protein expression patterns (US patent 6,197,599).
- arrays of cells, tissues, lipids, polymers, drugs and other chemical substances can be fabricated for large scale screening assays in medical diagnostics, drug discovery, molecular biology, immunology and toxicology (Kononen, et al., Nature Medicine, 4:844-7, 1998).
- Proteins are important component of cells and they are the real players in various cellular processes; and they are the targets of most drugs.
- the entire human genome encodes about 40,000 proteins.
- a given cell may contain the DNA encoding all the proteins, it usually only expresses a fraction of them.
- a cell line usually expresses about 10,000 proteins and an even higher number is expressed in tissues.
- the protein expression pattern of a cell determines its shape and function; and abnormal protein expressions cause diseases. Therefore, one major task of proteomics is to identify the proteins expressed in a given source.
- a protein (with an identical primary amino acid sequence) may be present in different forms in the cells largely due to posttranslational modifications. Since, in many cases, only special posttranslationally modified proteins are activated and directly involved in a cellular process, the detection of the presence of these activated proteins in the cells can provide valuable information on that cellular process.
- Quantification of protein expressions has applications in a variety of fields including biomedical research, disease diagnosis, identification of therapeutic markers and targets, and in profiling cellular responses to toxins and pharmaceuticals, hi basic biomedical research, it is usually desirable to know what proteins are expressed in specific cells or under specific conditions. And by comparing the protein expression profiles between different cell types, it is possible to identify those proteins whose expressions and activations characterize a particular cell type. In many signal transduction pathways, certain proteins are specifically activated; and the detection of these active proteins, e.g., phosphorylated proteins, may provide important information on the activations of specific signal transduction pathways.
- Protein expression profiling is useful in key areas of drug development, such as in drug target selection, toxicology and the identification of surrogate markers of drug response.
- Immunochemical staining is a versatile technique in determining both the presence and localization of an antigen (Harlow and Lane, Antibodies, a laboratory manual, Cold Spring Harbor Press, 1988), which information is of immense value in biomedical research and clinical medicine.
- Most of the current methods which employ the steps of incubating cells with an antibody solution, only allow cell staining with one or a few antibodies at a time. These methods are not suitable for applications in which the expressions and sub-cellular localizations of a large number of different proteins need to be examined. Therefore, a new method that is capable of staining cells with a large number of different antibodies is needed for such purposes.
- the preferred methods of invention are adapted to utilize various support materials and immobilization methods to make and use the arrays.
- the methods and arrays of the invention are designed to substantially expand the use of biological arrays in the field of detecting proteins and other biological molecules.
- arrays of antibodies immobilized on a first, preferably solid, support are contacted with a protein sample immobilized on a second support so that one or more of the antibodies bind to their respective antigens and, after binding, the antibodies are then dissociated from the first support while maintaining association with their antigens on the second support.
- a preferred method of the invention for detecting one or more biological molecules generally comprises the steps of: providing a first support on which one or more reagents are immobilized; providing a second support on which one or more ligands are immobilized; contacting the reagents immobilized on the first support with the ligands immobilized on the second support whereby one or more of the reagents bind to one or more of the ligands; separating the first support from the second support; and detecting one or more reagents on said second support.
- the reagents are preferably immobilized on said first support with strength sufficient to immobilize said reagents in the contacting step and yet allow said bound reagents to dissociate from said first support in said separating step.
- the reagents immobilized on said first support may comprise one or more antibodies.
- the ligands may be separated from each other before being immobilized on said second support using a variety of methods including, but not limited to: using gel electrophoresis based, at least in part, on their molecular weights; using gel electrophoresis based, at least in part, on their isoelectric points; using two-dimensional gel electrophoresis based at least in part on one or both of their molecular weights and isoelectric points; immunologically such as by using one or more antibody arrays.
- the reagents may be selected from a group consisting of antibodies, recombinant proteins, DNA, RNA, oligo nucleotides, carbohydrates, and small chemicals. The reagents may be immobilized at one or more predetermined positions on said first support. If the reagent selected is one or more antibodies, antibodies may be specific for posttranslationally modified proteins such as phosphorylated proteins.
- One or more of the reagents may be each immobilized at one or more predetermined positions on the support.
- the number of different kinds of reagents on any given support are preferably: 2 to 50; 5 to 100,000; 200 to 10,000; 50 to 1,000; 5 to 500; 5 to 100; and 5 to 50.
- the first or second support may comprise materials selected from a group consisting of nitrocellulose, nylon, polyvinylidene difluordie, glass, or plastic, and their derivatives.
- Another preferred method of the invention to detect one or more biological molecules in cells generally comprises the steps of: (a) immobilizing one or more antibodies on a first support, wherein said antibodies are provided at predetermined positions on said first support such that said antibodies can be identified by the position where they are immobilized; (b) placing said cells on a second support; (c) contacting said antibodies on said first support with said cells on said second support to allow said antibodies to bind to any corresponding antigens in said cells; (d) separating said first support from said second support whereby one or more of said bound antibodies remain bound to the corresponding antigens after separation; (e) detecting said antibodies bound to antigens in said cells on said second support.
- the method may utilize cells that are immobilized on said second support, wherein said cells may comprise one or more tissue sections.
- the antibodies may be specific for posttranslationally modified proteins such as phosphorylated proteins.
- the number of different kinds of reagents that can be immobilized at one or more predetermined positions may include 5 to 100,000; 200 to 10,000; 50 to 1,000; 5 to 500; and 2 to 50.
- the supports may comprise materials selected from a group consisting of nitrocellulose, nylon, polyvinylidene difluordie, glass, or plastic, and their derivatives. Proteins such as antibodies may be immobilized on the supports in one or more shapes selected from a group consisting of circular, elongated, and polygonal.
- the first or second support may comprise an array.
- the array may be made using various materials including, but not limited to, a plurality of whole or partial capillary tubes.
- the antibodies may be immobilized on said support using one or more intermediaries selected from a group consisting of modified protein A and modified protein G. Protein A or protein G are modified to alter its binding affinity.
- One or more of said antibodies may have at least one constant region, that is adapted to engage one or more of the modified proteins, and at least one variable region that is available to bind to one or more antigens.
- the step of detecting preferably comprises one or more steps of detecting selected from a group consisting of, determining whether one or more of said antibodies is present on one or both supports, identifying one or more locations of said antibodies after the separating step, determining one or more quantities of said antibodies, and identifying one or more types of antibodies.
- Another preferred method of the invention for detecting one or more biological molecules comprises the steps of: (a) immobilizing one or more ligands on a second support; (b) immobilizing one or more reagents, that are adapted to interact with one or more of said ligands, on a first support; (c) contacting said reagents with said ligands to allow one or more of said reagents to bind with one or more of said ligands; (d) cross- linking one or more said reagents with one or more of said ligands; (e) separating said first support from said second support to allow one or more of said reagents that are bound to one or more of said ligands to dissociate from said first support; (f) detecting one or more of said reagents on said second support.
- One or more of said ligands and said reagents may be cross-linked using, at least in part, one or more aldehydes which are preferably, but not necessarily limited to, formaldehyde and glutaldehyde.
- a preferred embodiment of one of the arrays oflhe invention for use in detecting biological molecules generally comprises: a first support adapted to at least temporarily immobilize one or more reagents and adapted to be placed in contact with a second support, to which one or more ligands are immobilized, so that one or more of said reagents is allowed to bind with one or more of said ligands and to subsequently dissociate from said first support and remain bound to said ligands on said second support.
- the supports may comprise various materials, including, but not limited to, one or more of the following materials: nylon, nitrocellulose, polyvinylidene difluordie, glass, or plastic, and their derivatives.
- the support may comprise one or more nylon membranes or a whole or a portion of one or more capillary tubes.
- One or more of said reagents are immobilized on a support may be immobilized in one or more shapes selected from a group consisting of circular, elongated and polygonal.
- the ligands may also be immobilized, at least in part, by covalent bonds.
- FIG. 1 is a schematic diagram of a preferred method of the invention for detecting multiple proteins.
- FIG. 2 shows the result after using a preferred method and array of the invention to detect multiple proteins.
- MDCK cells were stained with an array of 200 antibodies. The staining was observed via alkaline phosphatase-mediated color reaction with BCIP/NBT as substrates.
- FIG. 3 a shows the result after using a preferred method and array of the invention using fluorescent staining.
- An array of 200 rabbit polyclonal antibodies was used and the staining of protein IRFl at one position is shown here at a scale bar of 300 ⁇ m.
- FIG. 3b is a partial, enlarged view of the image in FIG. 3a at a scale bar of 30 ⁇ m.
- FIG. 3c shows the result after using a preferred method and array of the invention using fluorescent staining.
- An array of 200 rabbit polyclonal antibodies was used and the staining of signaling molecule 14-3-3 ⁇ at one position is shown.
- FIG. 3d is a partial, enlarged view of the image from FIG. 3c.
- FIG. 3e shows the result after using a preferred method and array of the invention using fluorescent staining.
- An array of 200 rabbit polyclonal antibodies was used and the staining of cell adhesion protein /3-catenin at one position is shown.
- FIG. 3f is partial, enlarged view of the image from FIG. 3e.
- FIG. 3g shows the result after using a preferred method and array of the invention using fluorescent staining.
- An array of 200 rabbit polyclonal antibodies was used and the staining of transcriptional factor Ets-1 at one position is shown here.
- FIG. 3h is a partial, enlarged view of the image from FIG. 3g.
- FIG. 4a shows the result after using a preferred method and array of the invention whereby A431 cells were stained with an array containing rabbit anti-YYl antibodies (left in green), mouse anti-pl30 cas antibodies (middle in red), and both YY1 (right in green) and pl30 cas (right in red) antibodies at neighboring positions. Goat anti-rabbit Cy2-labeled secondary antibodies and goat anti-mouse Cy3-labeled secondary antibodies were used.
- FIG. 4b is an enlarged view of the double staining of YY1 (green) and pl30 cas (red) shown in FIG. 4a.
- FIG. 5 shows the result after using a preferred method and array of the invention to detect protein expressions in two biological samples.
- Protein expressions in ME180 cells are shown at left and protein expressions in A431 cells are shown at right.
- Antibody arrays with 240 antibodies were used in this example. The staining was observed via alkaline phosphatase-mediated color reaction with BCIP/NBT as substrates.
- FIG. 6 shows the result using Western blotting to determine the differences in protein expression as detected in FIG. 5. Expressions of 19 proteins in ME180 cells (left lanes) and in A431 cells (right lanes) as detected by Western blotting are shown here. Proteins examined are: A, Cbl (120 kD); B, Cdc2 (34 kD); C, Cortactin (80 kD); D, Neu (185 kD); E, ERKl (44 kD); F, Ets-1 (51 kD); G, GSK-3 ⁇ (51 kD); H, HSP 70 (70 kD); I, JNKl (46 kD); J, Lyn (56 kD); K, NF/cB p50 (50 kD); L, Skp2 p45 (45 kD); M, p53 (53 kD); N, Plk3 (70 kD); O, SH-PTP2 (60 kD); P, Raf-1 (74 kD); Q,
- FIG. 7 shows the results after using a preferred method and array of the invention to detect protein expressions in a protein lysate of A431 cells separated by SDS/PAGE.
- Antibodies against 12 proteins were immobilized at proper positions. Proteins examined are: 1, IKK beta; 2, E2F1; 3, ERK2; 4, 14-3-3; 5, Rb pl07; 6, ERKl control (antibodies were immobilized at positions where there was no antigen); 7, Ets-1; 8, ERKl; 9, Statl; 10, 14-3-3 control; 11, JNKl; 12, Stat2; 13, Lyn; 14, p38.
- the corresponding position for each of the antibodies is indicated at the right of the corresponding spot.
- the invention relates to novel arrays of biological reagents and methods for making and using the arrays.
- the method generally feature the steps of providing a first support immobilized with one or more reagents, providing a second support immobilized with one or more ligands, contacting the reagents with the ligands whereby one or more of the reagents bind to the ligands, separating the supports after binding whereby the bound reagents remain bound to the ligands, and detecting and/or comparing various biological targets.
- One of the methods allows for a reagent, immobilized on a solid support, to bind its interacting partner that is immobilized on another support.
- antibody arrays are made so that the immobilized antibodies can dissociate from the support after binding their respective antigens that are immobilized on a second support. The binding of each antibody-antigen occurs at a pre-determined position.
- reaction refers to any molecules of biological interest, such as antibodies, recombinant proteins, synthesized peptides, DNA, RNA, nucleotides, and small chemicals.
- ligands refers to any biological molecule that is interactive with one or more reagents.
- array refers to a device that includes, but is not limited to, a solid support and a plurality of reagents or ligands.
- antibodies maybe immobilized on the support, each at a predefined position so that each antibody can be identified by a specific position on the support.
- immobilization means the restriction of a reagent on a support so that the movement of the reagent on the support is limited.
- immobilized reagent can dissociate from the support.
- the physical and chemical nature of the immobilization determines whether an immobilized reagent can dissociate from the support; and how efficient the dissociation will be.
- the term "support” is used herein, for the purposes of the specification and claims, to mean the structure on which biological reagents are deposited and immobilized.
- the supports may be, but are not limited to, rigid plates (glass or plastics) or membranes made of nitrocellulose, nylon, polyvinylidene difluoride (PVDF), or their derivatives. Membranes are easier to handle and reagents can be readily immobilized on them. Glass or plastic plates provide rigid support and are necessary in some applications.
- the solid supports are pretreated so that biological reagents deposited on them can be immobilized with adequate strength suitable for specific applications.
- One way to treat the solid support is to coat it with a layer of polymers that in turn will interact with biological reagents through non-specific, non-covalent bonds.
- polymers comprising polylysine or polyethyleneimine may be used to coat glass slides or coverslips for use in immobilizing biological molecules.
- adsorption forces involved may be nonspecific, hydrophobic or ionic interactions.
- adsorbent materials used include, but are not limited to, clay, charcoal, hydroxyapatite, and most frequently, ion-exchange materials such as DEAE- Sephadex.
- capillary tubes are used to facilitate arraying and immobilizing biological reagents.
- the term "capillary tube” is used herein, to mean any wholly or partially enclosed elongated structure capable of containing and supporting biological reagents.
- the capillary tubes may be made from materials such as plastics and glass, which preferably do not interfere with the properties of biological reagents.
- the heights of the capillary tubes may be varied from micrometers to meters.
- a biological reagent is usually filled into a capillary tube as liquid solution. After filling, the reagent solution becomes solidified and the reagent is immobilized.
- the strength of immobilization maybe varied depending on a given application.
- Reagents are immobilized on a solid support directly or indirectly.
- reagents may be directly deposited at high density on a support, which can be as small as a microscopic slide. Similar technology was developed for making high density DNA microarray (Shalon et al., Genome Research, 1996 Jul; 6(7): 639-645).
- Reagents may also be immobilized indirectly on the support. For instance, protein A or protein G, or their mutants can be first printed on a support as intermediates.
- Antibodies are then immobilized on the support through their interactions with protein A or G.
- One advantage of this method is that, by engaging the constant regions of antibodies with protein A or G, the variable regions of the antibodies (antigen-binding domains) will be fully exposed and available to bind antigens.
- Another advantage is that, since protein A or G can be modified to change their binding affinity for antibodies, when carefully designed mutants of protein A or protein G are used, antibodies can be immobilized on the support with desired strength. As such, antibodies on one hand can be immobilized on the support without losing positional information but on the other hand can leave the support and bind to other ligands of higher affinity. Recombinant fusion proteins can be immobilized through the interactions between their tags and the ligands attached on the support.
- ligands e.g., glutathione or nickel
- a support e.g., glutathione or nickel
- recombinant fusion proteins containing a tag e.g., GST or 6xHis
- the tags and ligands can be modified to change their affinities so that the immobilization will have desired strength.
- Antibodies are usually deposited on a support as circular dots. However, antibodies can also be deposited in other shapes. For example, antibodies can be immobilized in an elongated shape, such as a rectangular shape of a few microns to a few centimeters wide and a few microns to a few centimeters long. Antibodies immobilized in such a shape can be used to bind antigens after separation according to a variety of methods.
- An antibody specific for an antigen may be immobilized at a specific position on a support.
- antibodies are immobilized at positions that when they make contacts with protein samples, each antibody will make contact with its own antigens. Therefore, a specific antibody may be immobilized at a specific position which is determined by the position of its antigen. For example, when antigens are first separated by two-dimensional gel electrophoresis and transferred and immobilized on a support; each antigen is immobilized at a specific position determined by its molecular weight and isoelectric point. Therefore, each of the antibodies can be immobilized according to the position of the antigen on the support.
- protein sample refers to a variety of proteins and protein mixtures. For example, it can be a lysate from a cell line or tissue. Or it can be intact cells, or cells fixed on a support. A protein sample can be from different sources such as, but not limited to, cultured cell lines, human or animal tissue, or blood.
- protein samples are cultured cells or tissue sections that can be placed on glass slides and immobilized. Before use, the cells can be fixed and permeabilized to expose proteins. The fixed cells retain certain cell morphology and most proteins stay at their original cellular positions.
- fixation solution is a formaldehyde or glutaldehyde solution. Another commonly used fixation solution contains methanol instead.
- Suspension cells such as lymphocytes can be spun down on a support and immobilized on it. They may also be embedded in a medium, such as paraffin, collagen, gelatin, and then sectioned and placed on a support.
- a medium such as paraffin, collagen, gelatin.
- Many known methods are available to prepare cell samples (Jones, T.C, Ward, J.M., Mohr, U. and Hunt, R.D. (editors), 1990, Hemopoietic System. Berlin, Springer- Verlag; Polak, J.M. and Van oorden, S., 1997, Introduction to hnmunocytochemistry. New York, Springer).
- protein samples are prepared from cells or tissues by lysis.
- a typical lysis buffer contains detergents such as sodium dodecyl sulphate (SDS), Triton X-100, etc.
- SDS sodium dodecyl sulphate
- the immobilization of protein samples can be via covalent or non-covalent bond and methods for immobilization are known in the arts.
- the size of the area on which a protein sample is immobilized on the support may be different depending on applications and the volume and amount of the protein sample immobilized. For example, when a membrane is used as support, if the binding capacity of the membrane is 10 mg protein per square centimeter, then up to 10 mg of protein lysate can be immobilized on a membrane with a size of 1 square centimeter.
- proteins may be first separated and then immobilized on a support.
- Many methods for protein separations are known in the art. For example, proteins can be separated by one-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) according to molecular weight; or separated by 2- dimensional electrophoresis according to both molecular weight and isoelectric point. After separation by electrophoresis, proteins can be transferred and immobilized on a support.
- SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
- protein samples can be separated by immunological methods, such as separation by an antibody array.
- a protein sample is first incubated with an antibody array on a first support to allow antibodies to capture and therefore separate their antigens present in the protein sample. After washing away non- binding proteins, the proteins captured at each position are dissociated from the antibodies and transferred onto a second support and immobilized on it.
- the interactions between antibodies and the first solid support can be much stronger than the interactions between antibodies and antigens. Therefore, conditions may be found to disrupt antibody- antigen interactions but leave antibody immobilization on the first support intact. Under such conditions, the antigens but not the antibodies may be transferred onto the second support and immobilized on it. To avoid antibody dissociation from the first solid supports, the antibodies may be covalently immobilized on the supports.
- the first support containing the antibodies and the antigens is contacted with a second support. Then they are placed in a buffer solution that could disrupt the interactions between the antigens and antibodies. And at the same time, an electric current is applied so that the disassociated proteins will move from the first support to the second support. After completion the two supports are separated.
- the transfer and immobilization may take place simultaneously (proteins are transferred and immobilized at the same time) or sequentially (proteins are transferred first and then immobilized). And if the immobilization is not as strong as desired the proteins could be further immobilized, e.g., through covalent bond. Methods are known in the art for covalent immobilization of proteins on solid support.
- the protein samples are contacted with another antibody array.
- the contact is preferably carried out so that each antibody contacts its respective antigen to allow for specific binding.
- the antibodies on this array are dissociable from the support. Therefore, after separation of the antibody array support and the protein sample support, antibodies that bond to the antigens will be present on the sample support. By detecting the antibodies, the presence and abundance of antigens in the sample are detected.
- Some of the methods are adapted to allow antibodies immobilized on one support to bind antigens immobilized on another support.
- antibodies immobilized on one support are allowed to interact with antigens immobilized on a second support by placing the two supports together to make contact. After incubation for a certain time, the two supports are separated. Depending on the interactions between antibodies and antigens, some antibodies will dissociate from the first support and bind to the second support where antigens are immobilized.
- the strength of antibody immobilization on the first support is preferably weaker than the interactions between antibodies and antigens, and weaker than the strength of the immobilization of antigens on the second support. Conditions such as an electric field can be applied to facilitate the dissociation of the antibodies from the support.
- the antigen-antibody complexes can be stabilized using covalent cross-linking.
- the cross-linking is preferably performed in such a way that antibody-antigen complexes are cross-linked but the antibodies are not cross-linked on their support. This can be achieved by choosing specific cross-linkers and special support for antibodies.
- cross-linkers There are hundreds of known cross-linkers and a variety of methods have been developed to use them to cross-link proteins (Wong, Shan S., Chemistry of protein conjugation and cross-linking. Boca Raton: CRC Press, 1993).
- commonly used cross-linkers include aldehydes such as, but not limited to, formaldeyde and glutaldehyde.
- the antibodies bound to the antigens are then detected.
- Many known arts can be used to detect antibodies.
- a common method is to use enzyme-conjugated secondary antibodies, such as horseradish peroxidase or alkaline phosphatase conjugated goat anti- rabbit and goat anti-mouse antibodies. Fluorescent-labeled secondary antibodies can also be used.
- Other technologies that can be used include immuno-PCR (Sano et al., 1992, Science 258, 120-122), rolling circle DNA amplification technique (Schweitzer et al., 2000, Proc. Natl. Aead. Sci. USA 97, 10113-10119), and immuno-detection amphfied by T7 RNApolymerase (Zhang et al, 2001, Proc. Natl. Aead. Sci. USA, Vol. 98, 5497- 5502.).
- arrays of antibodies may be used to stain cells, which is shown schematically in FIG. 1.
- Cells can be seeded on a coverslip, cultured, fixed and permeabilized to expose the antigens.
- Cell preparations are then incubated with an antibody array to allow the antibodies to bind to their respective antigens. After binding, the antibody array support and the cell support are separated. Some of the antibodies will be transferred to the cell support due to their interactions with their antigens. The amount of the bound and transferred antibodies will be related to the amount of antigens present in the cells.
- the presence and quantities of their antigens in the cells can be determined. If the antibodies are conjugated with an enzyme, they can be revealed by enzymatic reactions. Alkaline phosphatase is commonly used and known substrates will give insoluble color products after reaction. In addition, if the antibodies are labeled with fluorescent molecules, they may also be observed directly under fluorescent microscopy. In many cases fluorescent- or enzyme-conjugated secondary antibodies can be used to reveal the presences of the primary antibodies.
- the staining may simply be observed at a low magnification. However, to reveal other properties of the antigens, such as their sub-cellular localizations, the staining is preferably observed at a higher magnification.
- Simultaneous staining of two proteins is a unique tool for studying two functionally related proteins. For example, evidence of protein interactions often includes the demonstration that the proteins co-localize in the same cellular structure.
- Two or more antibodies can be immobilized on the same position of the antibody array so that two or more antigens can be detected at the same location simultaneously.
- DNA probes instead of antibodies may be arrayed and used to detect the presence of specific DNA or RNA in the cells.
- DNA or RNA probes are immobilized on a solid support.
- the immobilization of the probes is strong enough to maintain probes' positions on the support; but are preferably weaker than the interactions between the probes and their targets, so that when the probes bind to their targets, the probes can dissociate from the support. This method has many advantages over in situ hybridization, which usually only detects one or a few DNA or RNA sequences.
- DNA or RNA probes made according to the present invention When an array of DNA or RNA probes made according to the present invention is used, the presence and locations of a large number of DNA or RNA sequences can be detected in morphologically preserved tissue sections or cell preparations, each at a pre-defined position.
- the methods for preparing DNA and RNA probes, to be arrayed on a support, and the methods for preparing tissues or cells are known in the art (Ian A. Darby (Editor), In Situ Hybridization Protocols (Methods in Molecular Biology, 123), by Humana Press; ISBN: 0896036863; 2nd edition, 2000).
- an antibody array is used to detect proteins in a protein lysate.
- an antibody array immobilized on a first support is incubated with a protein lysate immobilized on a second support. After incubation for certain time, the antibodies will bind their respective antigens in the lysate that are immobilized on the second support. Then the first support is separated from the second support. Under proper conditions, the antigen-bound antibodies will be dissociated from the first support and stay on the second support, on which their antigens are immobilized. The amount of an antibody transferred to the second support will be proportional to the abundance of its antigens in the protein lysate. Therefore, the detection of the amount of antibodies on the second support will reveal the abundance of their antigens in the protein sample.
- proteins can be first separated and/or concentrated, which may be necessary to detect low abundant proteins.
- proteins are first separated by one-dimensional SDS/PAGE and transferred to a membrane support so that each protein is immobilized on the support at the position determined by its molecular weight. Then the lysate membrane is contacted with an antibody array, in which antibodies are immobilized in elongated shapes at specific positions, so that each of the antibodies will be able to contact its antigen at the specific position determined by the molecular weight of that antigen.
- Proteins may also be separated by two-dimensional gel electrophoresis and transferred to a support such as a polyvinylidene difluoride (PNDF) membrane. Then the lysate membrane is contacted with an antibody array, which may contain multiple antibodies that each may be immobilized at a predetermined position so that each antibody will contact its corresponding antigen.
- PNDF polyvinylidene difluoride
- Proteins may also be separated and concentrated by immunological methods.
- One way to achieve this is to use antibody arrays.
- a first antibody array can be incubated with a protein sample so that the proteins are captured and separated by each antibody immobilized on the array.
- the antibodies in this first array are preferably strongly immobilized, e.g. via covalent bond.
- the antigens are dissociated from the antibodies and transferred and immobilized on a second support. This process can be performed with several known methods.
- a second antibody array is then used to detect the antigens.
- Antibodies on the second array are immobilized in such a way that after binding their respective antigens, antibodies can be dissociated from the array support.
- Antibodies in the first and second arrays against the same antigen may be immobilized at corresponding positions; and they can be identical or different.
- arrays of biological reagents include but are not limited to arrays of recombinant proteins, recombinant antibodies, single chain antibodies, nucleic acids, oligos, cD ⁇ A probes, carbohydrates, lipids, small chemicals.
- arrays of immobilized cD ⁇ A probes can be used in in situ hybridization to reveal the expressions of multiple mR ⁇ A in cells.
- Example 1 Making of antibody arrays.
- Antibodies from commercial sources were arrayed on Nylon membranes (from Amersham Life Science) using a robotic arrayer. About 40 ng antibodies in 80 nl solutions were deposited at each spot using a 0.6 mm solid pin, spaced 600 ⁇ m apart. Antibodies were immobilized by non-covalent bonds between nylon membranes and the antibodies. Antibody arrays were either used immediately or stored at 4 °C for less than 48 hrs before use.
- Example 2 Use of antibody array in immimochemical staining.
- This example is to demonstrate the use of antibody arrays prepared by the method disclosed for immunochemical staining.
- Antibody arrays made in Example 1 with 200 antibodies against different cellular proteins were used.
- MDCK cells Madin Darby Canine Kidney (MDCK) cells were seeded on a culture dish and cultured for 2 days until confluence. Then they were fixed and permeabilized in Methanol/ Acetone (1 : 1) for 10 min at -20 degree. After rinsing with phosphate-buffered saline (PBS), MDCK cells were contacted with an antibody array for about 1 hour. During the incubation the antibodies bound their antigens present in the cells. After that, antibody array support and cell support were separated. Cells were rinsed with phosphate-buffered saline again and alkaline phosphatase-labeled secondary antibodies were added for half an hour.
- PBS phosphate-buffered saline
- each staining spot is about 300- ⁇ m in diameter and consists of a cluster of 400 cells (FIG. 3a, 3c, 3e, and 3g). There are clear boundaries between the stained areas and non-stained areas.
- a high magnification observation revealed the detailed staining patterns, e.g., nuclei localization of IRF1 (FIG. 3b), cytoplasmic staining of 14-3-3 ⁇
- FIG. 3d and Ets-1 (FIG. 3f), and cell-cell contacts staining of beta-catenin (FIG. 3h).
- the staining is indistinguishable from that obtained with standard immunostaining procedure.
- Example 4 Antibody arrays made in capillary tubes.
- This example is to use antibody arrays made with capillary tubes to stain cells.
- Each antibody was mixed with low-melting agarose solution and injected into a plastic capillary tube of 1-cm high, 2-mm in outer diameter and about 0.2 mm thick. After the gel became solid, capillary tubes were bundled together and cut across section to produce arrays of about 1-mm high.
- Example 5 Antibody arrays made in capillary tubes for fluorescent immunostaining.
- Fluorescent-labeled antibodies were first mixed with a low-melting agarose solution at high temperature and then the antibody solutions were injected into capillary tubes to make a capillary array. Temperature was lowed to solidify the solutions in the capillary tubes. The tubes were then cut to make thin arrays; less than 1 mm high; and put on a plastic solid support and glued on it. The array was contacted with fixed cells which were placed on a cover glass to allow antibodies to contact antigens. Then the cells and antibody array were incubated at 37° C for 2 hrs. After that, temperature was lowed and the array and cells were separated. Cells on the cover glass were then washed with PBS and observed under microscope. Example 6: Use of antibody arrays in double staining.
- An antibody array was made that had 100 spots; each spot contained one or two antibodies. At the spots where two different antibodies were immobilized, one of them was mouse monoclonal and the other one was rabbit polyclonal.
- the array was. used to stain A431 cells seeded on a cover glass. After staining, A431 cells were incubated with Cy2-labeled goat anti-rabbit secondary antibodies and Cy3-labeled goat anti-mouse secondary antibodies. The presence and locations of the antigens were examined by fluorescent microscopy (FIG. 4a and 4b). At the positions where two antibodies were present, the two corresponding antigens were observed.
- the two antibodies/antigens can be distinguished by different labeling and different cellular localizations. For example, in FIG. 4 the nuclear localization of protein YY1 and membrane localization of protein pl30 cas were seen individually (FIG.4a, left and middle) and together (FIG. 4a, right; and FIG. 4b).
- Example 7 Use of antibody array staining to compare protein expressions between cell samples.
- Antibody arrays containing both mouse monoclonal and rabbit polyclonal antibodies against 240 proteins involved in various signaling pathways were produced as described in previous examples. And the presence of the 240 proteins were detected and compared between A431 cells, and ME180 cells, two human cancer cell lines that are widely used in research. The result showed that the two cell samples have very different protein expression patterns. Many of the 240 target proteins are expressed differently in A431 and ME180 cells (FIG. 5). For example, A431 cells express more Cbl, cortactin, Neu, HSP 70, JNKl, p53, Raf-1, and Statl; but less GSK-30-, Skp2 p45, Plk3, and Stat5a than ME180 cells.
- Example 8 Detecting pathway activation with antibody arrays.
- Antibodies that are specifically against activated proteins were used to make antibody arrays and the arrays were used to examine the presence of these activated proteins in a biological sample. The presence of activated proteins suggested that certain signal transduction pathways were activated in the sample.
- Example 9 Detection of specific proteins in a protein lysate.
- Example 11 Staining with antibody array immobilized via protein A mutant.
- a recombinant protein A mutant with one antibody binding domain was first immobilized on a support; and then HRP-conjugated antibodies were immobilized on the support via interaction with the protein A mutant to form an antibody array.
- Such made antibody array was contacted with a protein lysate immobilized on another support. After 1 hr incubation, the antibody array was removed and the antibodies bound to the protein sample support were detected via ECL reaction.
- Example 12 Separation of protein samples by SDS/PAGE.
- protein lysates of A431 cells were separated by SDS/PAGE using a curtain gel and transferred to a PVDF membrane.
- Antibody arrays containing 12 antibodies against well-studied proteins were made using nylon membrane as support and used in the assay. The antibodies were immobilized in rectangular shapes and were carefully positioned on the array so that when the arrays made contacts with the protein lysate immobilized on the PVDF membrane, antibodies can bind their respective antigens. After binding between antibodies and antigens, nylon membrane support was removed from the PVDF membrane. The antibodies that attached on the PVDF membrane via interactions with respective antigens were detected using HRP-conjugated secondary antibodies and revealed by ECL reaction. As shown in FIG. 7, several antigens were detected as expressed in A431 cells.
- Example 13 Separation of protein samples by two-dimensional gel electrophoresis.
- Example 14 Separation of protein samples by antibody arrays.
- proteins are first separated and concentrated by antibody arrays.
- An antibody array was made by immobilizing antibodies on a support covalently; then the array was incubated with a protein sample so that the proteins were captured and separated by each antibody immobilized on the array. Then the antigens were dissociated from the antibodies and transferred and immobilized on a sample support. Because the antibodies were covalently immobilized, no or very littler was transferred to the sample support.
- a second antibody array was then made in such a way that antibodies against the same antigen were at the same relative positions as the antibodies were in the first antibody array. When the second antibody array contacted the sample support on which antigens were immobilized, each of the antibodies made contact with respective antigen and bound to it. After binding, the array was separated from the sample support. Because some antibodies bound their antigens, they dissociated from the array support and bound to the sample support.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US329311P | 2001-10-01 | ||
US32931101P | 2001-10-16 | 2001-10-16 | |
PCT/US2002/019346 WO2003029490A1 (en) | 2001-10-01 | 2002-06-18 | Methods and arrays for detecting biological molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1432817A1 EP1432817A1 (en) | 2004-06-30 |
EP1432817A4 true EP1432817A4 (en) | 2006-12-27 |
Family
ID=37440483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02742197A Withdrawn EP1432817A4 (en) | 2001-10-16 | 2002-06-18 | Methods and arrays for detecting biological molecules |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1432817A4 (en) |
WO (1) | WO2003029490A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503980A (en) * | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5948621A (en) * | 1997-09-30 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Direct molecular patterning using a micro-stamp gel |
WO2000009464A1 (en) * | 1998-08-17 | 2000-02-24 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
WO2000027521A1 (en) * | 1998-11-06 | 2000-05-18 | Solexa Ltd. | A method for reproducing molecular arrays |
EP1006363A2 (en) * | 1998-12-01 | 2000-06-07 | Hitachi Software Engineering Co., Ltd. | Biochip and method for producing the same |
WO2001069247A2 (en) * | 2000-03-17 | 2001-09-20 | Bioinvent International Ab | Methods of making and using microarrays of anti-ligands for the analysis of protein expression in cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
WO1992015708A1 (en) * | 1991-02-27 | 1992-09-17 | Amoco Corporation | Methods for improving the sensitivity of hybridization assays |
JP3097866B2 (en) * | 1991-10-15 | 2000-10-10 | マルティライト リミティド | Binding assays using labeling reagents |
US6180348B1 (en) * | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
-
2002
- 2002-06-18 WO PCT/US2002/019346 patent/WO2003029490A1/en active Application Filing
- 2002-06-18 EP EP02742197A patent/EP1432817A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503980A (en) * | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5948621A (en) * | 1997-09-30 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Direct molecular patterning using a micro-stamp gel |
WO2000009464A1 (en) * | 1998-08-17 | 2000-02-24 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
WO2000027521A1 (en) * | 1998-11-06 | 2000-05-18 | Solexa Ltd. | A method for reproducing molecular arrays |
EP1006363A2 (en) * | 1998-12-01 | 2000-06-07 | Hitachi Software Engineering Co., Ltd. | Biochip and method for producing the same |
WO2001069247A2 (en) * | 2000-03-17 | 2001-09-20 | Bioinvent International Ab | Methods of making and using microarrays of anti-ligands for the analysis of protein expression in cells |
Non-Patent Citations (1)
Title |
---|
See also references of WO03029490A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003029490A1 (en) | 2003-04-10 |
EP1432817A1 (en) | 2004-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9023766B2 (en) | Method and arrays for detecting biological molecules | |
US6197599B1 (en) | Method to detect proteins | |
Zhu et al. | Protein chip technology | |
Schweitzer et al. | Microarrays to characterize protein interactions on a whole‐proteome scale | |
US6602661B1 (en) | Methods and arrays for detecting biomolecules | |
Chen et al. | Protein microarrays | |
MacBeath | Protein microarrays and proteomics | |
Templin et al. | Protein microarrays: promising tools for proteomic research | |
US20040171068A1 (en) | Method for producing stable, regeneratable antibody arrays | |
WO2001014425A1 (en) | Multipurpose diagnostic systems using protein chips | |
KR20030094404A (en) | Global analysis of protein activities using proteome chips | |
JP2004517297A (en) | Biochip for archiving and clinical analysis of biological sample materials | |
Huels et al. | The impact of protein biochips and microarrays on the drug development process | |
US8709789B2 (en) | Methods and devices for rapid and specific detection of multiple proteins | |
Eickhoff et al. | Protein array technology: the tool to bridge genomics and proteomics | |
EP1937848B1 (en) | In situ assembly of protein microarrays | |
US20040067539A1 (en) | Method of making and using microarrays of biological materials | |
US9714948B2 (en) | Method for high-throughput protein detection with two antibody microarrays | |
JP2005504309A (en) | Methods and arrays for detecting biomolecules | |
Feilner et al. | Proteomic studies using microarrays | |
WO2003029490A1 (en) | Methods and arrays for detecting biological molecules | |
US20010053520A1 (en) | Methods of making and using microarrays of biological materials | |
US20030082560A1 (en) | Method of making interactive protein arrays | |
O'Connor et al. | Protein chips and microarrays | |
Kumaresan et al. | Screening chemical microarrays: methods and applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030630 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20061123 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01J 19/00 20060101ALI20061117BHEP Ipc: G01N 33/68 20060101ALI20061117BHEP Ipc: G01N 33/543 20060101ALI20061117BHEP Ipc: G01N 33/50 20060101ALI20061117BHEP Ipc: C12Q 1/68 20060101AFI20030415BHEP |
|
17Q | First examination report despatched |
Effective date: 20090130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090103 |